๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma?

โœ Scribed by Maria Pleguezuelo; Laura Marelli; Sergio Maimone; Pinelopi Manousou; Elias Xirouchakis; Andrew K. Burroughs


Publisher
Current Science Inc.
Year
2008
Tongue
English
Weight
306 KB
Volume
7
Category
Article
ISSN
1540-3416

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Does interferon therapy for chronic hepa
โœ Anna S. F. Lok ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 413 KB

Objective: To estimate the cost-effectiveness of interferon-a2B for the treatment of patients with chronic hepatitis B infection who are positive for hepatitis B e antigen (HBeAg). Design: Meta-analysis of nine randomized controlled trials and cost-effectiveness analysis, projecting the clinical an

Case-control study on hepatitis C virus
โœ Alessandro Tagger; Francesco Donato; Maria L. Ribero; Roberta Chiesa; Giuseppe P ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 70 KB ๐Ÿ‘ 3 views

We performed a case-control study to evaluate the risk of hepatocellular carcinoma (HCC) for hepatitis C virus (HCV) infection. A total of 305 newly diagnosed HCC cases (80% males) and 610 subjects (81% males) unaffected by clinically evident hepatic disease admitted to the 2 main hospitals in Bresc